New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
07:54 EDTZGNXZogenix weakness creates buying opportunity, says Oppenheimer
Oppenheimer believes that the recent weakness in Zogenix has been caused by media headlines that rehashed the controversy regarding the approval of its Zohydro drug, as well as a misunderstanding of the company's comments regarding its use of cash. The firm does not expect the FDA to reverse its approval of the drug, and it views the change in the company's Q4 EPS as a result of a non-cash charge as " an accounting artifact." The firm keeps a $5 price target and Outperform rating on the stock.
News For ZGNX From The Last 14 Days
Check below for free stories on ZGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
17:15 EDTZGNXArmistice Capital reports 5.9% passive stake in Zogenix
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use